Test systems in Drug Discovery for hazard identification and risk assessment of human Drug-Induced Liver Injury.


Weaver, RJ, Betts, C, Blomme, EAG, Gerets, HHJ, Gjervig Jensen, K, Hewitt, PG, Juhila, S, Labbe, G, Liguori, MJ, Mesens, N et al (show 6 more authors) (2017) Test systems in Drug Discovery for hazard identification and risk assessment of human Drug-Induced Liver Injury. Expert opinion on drug metabolism & toxicology, 13 (7). pp. 767-782.

[img] Text
MS DILI Test Systems Manuscript EFPIA text tables 03_06_17 RW Clean.docx - Author Accepted Manuscript
Download (201kB)

Abstract

Introduction The liver is an important target for drug-induced toxicities. Early detection of hepatotoxic drugs requires use of well-characterized test systems, yet current knowledge, gaps and limitations of tests employed remains an important issue for drug development. Areas Covered The current state of the science, understanding and application of test systems in use for the detection of drug-induced cytotoxicity, mitochondrial toxicity, cholestasis and inflammation is summarized. The test systems highlighted herein cover mostly in vitro and some in vivo models and endpoint measurements used in the assessment of small molecule toxic liabilities. Opportunities for research efforts in areas necessitating the development of specific tests and improved mechanistic understanding are highlighted. Expert Opinion Use of in vitro test systems for safety optimization will remain a core activity in drug discovery. Substantial inroads have been made with a number of assays established for human Drug-induced Liver Injury. There nevertheless remain significant gaps with a need for improved in vitro tools and novel tests to address specific mechanisms of human Drug-Induced Liver Injury. Progress in these areas will necessitate not only models fit for application, but also mechanistic understanding of how chemical insult on the liver occurs in order to identify translational and quantifiable readouts for decision-making.

Item Type: Article
Uncontrolled Keywords: Human, hepatocytes, HepaRG, HepG2, DILI, liver, drug discovery, drug development, hepatobiliary, cytotoxicity, mitochondrial toxicity, cholestasis, immune system, IMI, test systems, endpoints
Depositing User: Symplectic Admin
Date Deposited: 15 Jun 2017 10:33
Last Modified: 19 Jan 2023 07:02
DOI: 10.1080/17425255.2017.1341489
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3007995
Dimensions
Altmetric
CORE (COnnecting REpositories)